Alternatively, the proteins could be modified post-translationally in a larval system.27–29 One example is tyrosinase with pathogenic mutations causing oculocutaneous albinism type 1A.30,31 Therefore, we hope that biochemical, computational, and clinical validation for a large multi-domain protein like an MYO7A will be possible in the future. The gene discussed is MYO7A; the disease is oculocutaneous albinism type 1A.